Novanta (NOVT)
NASDAQInformation TechnologyHardware, Equipment & PartsSnapshot 2026-09-09
$145.76-2.38%
Close 2026-09-09 · 1-day change
NASDAQInformation TechnologyHardware, Equipment & PartsSnapshot 2026-09-09
Broken: Primary pillar broken — Operating income near $27.5 million next quarter: Q2 operating income $18.1M vs $27.5M target.
Novanta grew revenue 10% last quarter. It aims for $1.05B revenue in 2026. The company bought Riverpoint Medical to grow. Profit margins need to improve but sales keep rising.
Profit fell from $32.4M to $27.5M last quarter. The stock dropped 10% recently. The company’s guidance is soft. Debt and equity sales may pressure the balance sheet.
The price is 53% above our fair value near $98. Analysts expect 8% revenue growth. We see risk from soft guidance and margin pressure.
Breaks if: Acquisition fails to add growth or causes financial strain
Breaks if: Operating income falls below $27.5 million next quarter
Breaks if: Revenue falls below $975 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on organic revenue growth and strategic acquisitions. The current thesis is characterized by medium confidence due to recent volatility in management and financial performance.
The market appears to have priced in a durable premium compared to peers, suggesting high expectations for future performance. With an expectations gap of 0.15, there is a belief that NOVT can sustain its growth trajectory despite being viewed as expensive.
Fundamentals are likely to remain stable, supported by management's focus on revenue growth and margin enhancement. Recent financial performance shows positive trends, but the company has a history of misses, which adds some risk.
The thesis hinges on several factors, including management's ability to maintain guidance, the potential for favorable macroeconomic conditions like Fed rate cuts, and the performance of sector leaders that can influence overall market sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this view. Profits are outpacing sales, which improves margins. There are no current threats to the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Novanta aims to drive mid-single-digit organic revenue growth with new product launches and strong commercial execution.
Over the next 1 to 3 years, NOVT's performance will depend on its execution of growth strategies and external market conditions. Not investment advice.